Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia
Figure 5
The addition of methotrexate, vincristine or L-asparaginase resensitizes BIM deletion-containing CCRF-CEM clones to dexamethasone.
Cell viability was measured by MTS assay after (A) methotrexate (MTX) (1 µM), (B) vincristine (VCR) (2 ng/ml), or (C) L-asparaginase (ASP) (0.5 IU/ml) was used singly or in combination with dexamethasone (DEX) (0.1 µM) for 48 h. Values obtained for treated cells were normalized to the untreated control for the same genotype. Error bars indicate SEM (n = ) of 3 independent replicates.